FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely, infectious diseases, and can be used to assess the severity of a patient's condition at HIV infection. To do this, the patient is examined to identify the condition of his individual organs and systems and to assess the patient's condition on a point system with the subsequent conclusion about the state by the value of the integral indicator. Additionally, determine comorbid conditions and diseases, and also determine HIV RNA as an indicator of viral activity and CD4-lymphocyte content in the blood. Determine the integral indicator of the patient's condition (II) by the formula: , FE where Nn – quantitative assessment in points for individual co-infections and diseases, presented in Table 1. With an II value of less than 100, it is concluded that the patient is in a satisfactory and stable state, 100 ≤ II < 300 – of moderate severity; 300 ≤ II < 500 – sever and with meaning II ≥ 500 – extremely sever.
EFFECT: usage of this method makes it possible to assess the severity of the patient's condition in HIV infection, taking into account the comorbidity, viral activity and the state of immunity.
1 cl, 2 tbl
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR AETIOLOGICAL VERIFICATION OF CYTOMEGALOVIRAL PNEUMONIA IN HIV-INFECTED PATIENTS | 2019 |
|
RU2728589C1 |
METHOD OF PREDICTING EFFICIENCY OF ANTIRETROVIRAL THERAPY IN CASE IN HIV-INFECTION | 2009 |
|
RU2414858C1 |
METHOD OF AETIOLOGICAL VERIFICATION OF CYTOMEGALOVIRUS ENCEPHALITIS IN PATIENTS WITH HIV INFECTION | 2023 |
|
RU2812981C1 |
METHOD FOR LABORATORY PERSONALIZED DIAGNOSTICS OF THE STATE OF IMMUNITY OF PATIENTS AND A SET OF OLIGODEOXYRIBONUCLEOTIDE PRIMERS, AND FLUORESCENTLY LABELED PROBES, AND STANDARD SAMPLES | 2022 |
|
RU2786211C1 |
DIAGNOSTIC TECHNIQUE FOR HEPATIC CIRRHOSIS (STAGE F4) IN THE OUTCOME OF CHRONIC VIRAL HEPATITIS C | 2019 |
|
RU2724595C1 |
METHOD OF PROGNOSTIC ASSESSMENT OF HEPATOTOXICITY IN HIV-INFECTED PATIENTS DURING ANTIRETROVIRAL THERAPY BASED ON THE DETERMINATION OF DELETION POLYMORPHISM OF GSTM1, GSTT1, CYP2D6 HUMAN XENOBIOTIC BIOTRANSFORMATION GENES AND A SET OF OLIGODEOXYRIBONUCLEOTIDE PRIMERS AND FLUORESCENTLY LABELED PROBES | 2022 |
|
RU2807530C1 |
METHOD FOR LABORATORY PERSONALIZED DIAGNOSTICS OF THE IMMUNE CONDITION OF NEWBORNS AND SET OF OLIGODEOXYRIBONUCLEOTIDE PRIMERS AND FLUORESCENTLY LABELED PROBES | 2019 |
|
RU2756979C2 |
METHOD FOR LABORATORY DIAGNOSIS OF STAGES OF HEPATIC FIBROSIS IN CHRONIC VIRAL HEPATITIS C | 2015 |
|
RU2583939C1 |
METHOD OF PREDICTION OF COGNITIVE DISORDERS IN PATIENTS WITH BRAIN CONCUSION AND MINOR BRAIN INJURY | 2023 |
|
RU2803276C1 |
METHOD FOR PREDICTION OF LETHAL OUTCOME IN CLINICAL COURSE OF COINFECTION OF HIV AND TUBERCULOSIS, ACCOMPANIED BY MULTIPLE DRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS | 2019 |
|
RU2710266C1 |
Authors
Dates
2018-10-24—Published
2017-03-30—Filed